RxDoctor Payments Data

Jose Arnao

Corneal and Contact Management · Gainesville, FLNPI 1417185364

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 206 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 38.9% of the total. Reporting peaked in 2023 at $1,196 and has fallen 50.3% since, to $594 in 2025.

$5,303in general payments, 2019–2025

Across 206 payments — averaging $25.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$2K
  • Novartis$770
  • Alcon$673
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$541
  • Sun Pharmaceutical Industries Inc.$216
  • ABB Con-cise Optical Group LLC$205
  • plus $837 from 11 others

What the payments were for

  • Food & beverage$5,285100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,303 in reported general payments places this provider in the 85th percentile of 67 corneal and contact management providers in Florida.

See all corneal and contact management providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine161$121,173
XiidraLifitegrast34$36,388
LumiganBimatoprost11$7,035
RocklatanNetarsudil Mesylat/Latanoprost17$6,522
CombiganBrimonidine Tartrate/Timolol19$5,232
Cyclosporine14$4,675
Timolol Maleate20$683
Dorzolamide Hcl13$258
Latanoprost27$79

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$42$133,440191 claims
Bausch & Lomb Americas Inc.Xiidra$2,060$36,38834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 67 corneal and contact management providers in Florida.

Other corneal and contact management in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →